Home » Authors » Brady Huggett

Articles by Brady Huggett

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Sep. 23, 2003

By Brady Huggett

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Sep. 23, 2003

By Brady Huggett

Antigenics Raising $31.6M Via Stock Sale To Single Investor

Sep. 22, 2003

By Aaron Lorenzo and Brady Huggett

Memory Signs Roche To $150M Expansion Of CNS Collaboration

Sep. 19, 2003

By Brady Huggett

Memory Signs Roche To $150M Expansion Of CNS Collaboration

Sep. 19, 2003

By Brady Huggett

ParAllele, Roche Seek Mutations Associated With Type II Diabetes

Sep. 17, 2003

By Brady Huggett

ParAllele BioScience Inc., as part of its move to the commercial side of things, signed a deal with Hoffmann-La Roche Inc. to discover genes and genetic variations around Type II diabetes. (BioWorld Today)

ParAllele, Roche Seek Mutations Associated With Type II Diabetes

Sep. 17, 2003

By Brady Huggett

ParAllele BioScience Inc., as part of its move to the commercial side of things, signed a deal with Hoffmann-La Roche Inc. to discover genes and genetic variations around Type II diabetes. (BioWorld Today)

Armed With Macugen, Eyetech Joins IPO Queue, Seeks $100M

Sep. 16, 2003

By Brady Huggett

Armed With Macugen, Eyetech Joins IPO Queue, Seeks $100M

Sep. 16, 2003

By Brady Huggett

Tercica, Armed With Genentech Technology, Seeks $86.25M IPO

Sep. 15, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...